← Browse by Condition
Medical Condition
egf r positive non small cell lung cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT06109558 Phase 1, Phase 2
Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Enrollment
120 pts
Location
China
Sponsor
Hunan Province Tumor Hospital
NCT06352502
Recruiting
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Enrollment
30 pts
Location
China
Sponsor
Tang-Du Hospital